Back to News
Market Impact: 0.25
Allarity Gets Japanese Patent For Stenoparib DRP Companion Diagnostic; Protection Through 2039
Source: Nasdaq
Patents & Intellectual PropertyHealthcare & BiotechTechnology & Innovation
Allarity Therapeutics announced that the Japan Patent Office granted a key patent for its stenoparib-specific Drug Response Predictor companion diagnostic. The patent strengthens intellectual-property protection for Allarity's personalized cancer-treatment platform in Japan, though the announcement does not include clinical, revenue, or regulatory-approval data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
ALLR0.75
More News
- Allarity Therapeutics secures first CLIA lab services contract
- Nasdaq Nears Correction as Amazon, Alphabet, Intel Disappoint Wall Street
- Wall Street Punishes Tech Stocks on Earnings Misses
- Reddit stock plunges 30% after weak outlook, heads for worst day ever
- Canada expects to seal a deal in June to become the EU’s first ‘associate member’ — ‘everything short of full EU membership’
- Are Houthis using Russian satellites as Saudi Arabia fends off strikes?